<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026817</url>
  </required_header>
  <id_info>
    <org_study_id>HM-MERO-104</org_study_id>
    <nct_id>NCT02026817</nct_id>
  </id_info>
  <brief_title>Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 10mg</brief_title>
  <official_title>An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 750/10 mg and Coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetic characteristics between HCP1201 tablet 750/10 mg and
      co-administration of metformin 750 mg plus rosuvastatin 10 mg under fed state condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After
      the Administration of HCP1201 Tablet 750/10 mg and Coadministration of Metformin SR 750 mg
      and Rosuvastatin 10 mg in Healthy Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>metformin, rosuvastatin Cmax</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>metformin, rosuvastatin AUClast</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin Tmax</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin T1/2</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin AUCinf</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>HCP1201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single oral dose of the HCP1201 750/10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin and Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received a single oral dose of coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1201 750/10mg</intervention_name>
    <description>750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.</description>
    <arm_group_label>HCP1201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin SR 750mg</intervention_name>
    <description>Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.</description>
    <arm_group_label>Metformin and Rosuvastatin</arm_group_label>
    <other_name>Glucophage SR 750 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10mg</intervention_name>
    <description>Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.</description>
    <arm_group_label>Metformin and Rosuvastatin</arm_group_label>
    <other_name>Crestor 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteer, age 20~55 years

          -  The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 27 kg/m2

          -  Subject who has the ability to comprehend the study objectives, contents and the
             property of the study drug before participating in the trial.

        Exclusion Criteria:

          -  Presence of medical history or a concurrent disease that may interfere with treatment
             and safety assessment or completion of this clinical study

          -  History of relevant drug allergies or clinically significant hypersensitivity
             reaction.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Ryul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2014</study_first_submitted>
  <study_first_submitted_qc>January 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2014</study_first_posted>
  <last_update_submitted>March 10, 2014</last_update_submitted>
  <last_update_submitted_qc>March 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

